Biopsy News and Research

RSS

Biopsy is the removal of cells or tissues for examination by a pathologist. The pathologist may study the tissue under a microscope or perform other tests on the cells or tissue. There are many different types of biopsy procedures. The most common types include: (1) incisional biopsy, in which only a sample of tissue is removed; (2) excisional biopsy, in which an entire lump or suspicious area is removed; and (3) needle biopsy, in which a sample of tissue or fluid is removed with a needle. When a wide needle is used, the procedure is called a core biopsy. When a thin needle is used, the procedure is called a fine-needle aspiration biopsy.

Viewpoints: Debating P4P; ‘Tactical retreat' by GOP; The virtues of across-the-board spending cuts

Instead of granting automatic pay increases, N.Y. City's public hospital system will pay them based on how well they reduce costs, increase patient satisfaction and improve the quality of care. The Health and Hospitals Corporation, which runs the city's 11 public hospitals, deserves praise for an ambitious proposal that will need to be refined as it is put into practice.

28 Jan 2013

Millennium, Seattle Genetics commence ADCETRIS plus chemotherapy phase III trial in MTCL

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502), today announced the initiation of a global phase III clinical trial evaluating ADCETRIS (brentuximab vedotin) in combination with chemotherapy for the treatment of newly diagnosed CD30-positive mature T-cell lymphoma (MTCL) patients, including patients with systemic anaplastic large cell lymphoma (sALCL) and other types of peripheral T-cell lymphomas.

28 Jan 2013

Novartis receives FDA approval for Exjade to treat chronic iron overload in NTDT patients

The U.S. Food and Drug Administration today expanded the approved use of Exjade (deferasirox) to treat patients ages 10 years and older who have chronic iron overload resulting from a genetic blood disorder called non-transfusion-dependent thalassemia (NTDT).

23 Jan 2013

Dutasteride decreases risk of biopsy detectable prostate cancer by 22.8%

The four-year REDUCE (REduction by DUtasteride of prostate Cancer Events) clinical study evaluated prostate cancer risk reduction in men taking dutasteride, a 5-alpha-reductase inhibitor (5ARI) typically used to treat enlarged prostate.

22 Jan 2013

Study to determine prevalence of abnormal anal cytology and HPV in at-risk women

A basic connection of statistics lead a researcher at Women & Infants Hospital of Rhode Island to question whether women should be screened for anal cancer during a regular visit to the gynecologist, and what technique is most effective.

18 Jan 2013

Argon Medical to launch Cleaner15 technology for mechanical thrombectomy procedures

Furthering its commitment to advancing the treatment of patients diagnosed with ESRD (End Stage Renal Disease), Argon Medical Devices, Inc. takes another leap forward with the launch of the Cleaner15 Rotational Thrombectomy System.

17 Jan 2013

Study demonstrates ways in which quality measurement from EHRs can be improved

Health care providers and hospitals are being offered up to $27 billion in federal financial incentives to use electronic health records (EHRs) in ways that demonstrably improve the quality of care. The incentives are based, in part, on the ability to electronically report clinical quality measures.

16 Jan 2013

NEDD9 gene controls growth of progenitor cells that give rise to breast tumors

Breast cancer is the second leading cause of cancer deaths among women in the United States. Many of these deaths occur when there is an initial diagnosis of invasive or metastatic disease. A protein called NEDD9-which regulates cell migration, division and survival-has been linked to tumor invasion and metastasis in a variety of cancers.

16 Jan 2013

Aggressive breast cancer’s metastasis molecular switch identified

Scientists at Weill Cornell Medical College have discovered the molecular switch that allows aggressive triple negative breast cancer cells to grow the amoeba-like protrusions they need to crawl away from a primary tumor and metastasize throughout the body. Their findings, published in Cancer Cell, suggest a novel approach for developing agents to treat cancer once it has spread.

15 Jan 2013

Targeted prostate biopsies skew proportion of high-risk cases

Image-targeted biopsy of the prostate leads to a substantial increase in the proportion of prostate cores identified as high risk compared with standard transrectal ultrasound-guided biopsy, the results of a UK study indicate.

14 Jan 2013

EHR implementation with technical support can improve patient care in small physician practices: Study

The relationship between a physician practice's adoption of electronic health records (EHR) and quality improvements in patient care remains unclear.

7 Jan 2013

JAMA column outlines need for frozen, larger specimens in DNA-sequencing era

Genetic sequencing technology is altering the way cancer is diagnosed and treated, but traditional specimen handling methods threaten to slow that progress.

7 Jan 2013

Local conjunctival metastases ‘may be under-recognized’

Local conjunctival metastases may represent under-recognized lesions arising from the dissemination of primary conjunctival melanoma via local vessels, suggest findings published in the British Journal of Ophthalmology.

4 Jan 2013

Partin Tables to predict prostate cancer spread now updated

Prostate cancer experts at Johns Hopkins have developed an updated version of the Partin Tables, a tool to help men diagnosed with prostate cancer and their doctors to better assess their chance of a surgical cure. The updated tool, based on a study of more than 5,600 men treated at The Johns Hopkins Hospital from 2006 to 2011, is published in the Jan. 3 issue of the British Journal of Urology International.

3 Jan 2013

Trovagene, MD Anderson partner to detect transrenal BRAF mutations in metastatic cancers

Trovagene, Inc., a developer of transrenal molecular diagnostics, announced that it has entered into a clinical collaboration with The University of Texas MD Anderson Cancer Center to detect transrenal BRAF mutations in the urine of patients with advanced or metastatic cancers.

3 Jan 2013

Circulating endothelial cells hit the mark in primary central nervous system vasculitis

Circulating endothelial cells may be a promising, non-invasive means of diagnosing and monitoring primary central nervous system vasculitis, researchers report.

2 Jan 2013

Active surveillance of prostate cancer patients encouraged

Active surveillance is an effective way of monitoring patients with low-risk prostate cancer and is associated with a low risk for systemic progression, say researchers.

31 Dec 2012

Trovagene adds Duke University Health System to worldwide licensees of NPM1 marker for AML

Trovagene, Inc., a developer of transrenal molecular diagnostics, announced it has granted Duke University and Duke University Health Systems a non-exclusive license to incorporate nucleophosmin protein (NPM1) into research and clinical testing services for acute myelogenous leukemia (AML).

27 Dec 2012

Implementation of appropriateness criteria required for elective procedures

Many of the most common inpatient surgeries in the United States are performed electively. These surgeries are expected to significantly increase with the enactment of the Affordable Care Act.